 |
5 Diseases |  |
20 Trials |
|
20 Trials |  |
1129 News |  |
| «12345678910111213» |
- Healthcare Resource Use (HRU) and Costs for Patients Living with Osteogenesis Imperfecta (OI): Results from US Retrospective Claims (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1513;
- Disability, functional limitation, and use of anti-fracture drug therapies in a cohort of 3651 U.S. adults with osteogenesis imperfecta (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1488;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
The Influence of Physical Function on Osteoporosis Treatment: A Study with Romosozumab. (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1472;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Promoted Bone Regeneration of Critical-Size Ulnar Defect Filled with Demineralized Bone Matrix in Non-Human Primates (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1467;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Effective Management of Osteoporosis Related to Pregnancy and Lactation Using Romosozumab: A Clinical Case Report (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1461;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Improves Areal BMD at the Axial Skeleton but not Areal and Volumetric BMD, Microarchitecture, and Strength at the Peripheral Skeleton in a Real-World Cohort (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1455;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Expected Fracture Outcomes and Associated Costs of Romosozumab Preceding or Following Alendronate in Postmenopausal Women at Very High Fracture Risk in the United States (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1453;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab and denosumab combination therapy in post-menopausal osteoporosis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1450;
- Fracture Rates for Patients Living with Osteogenesis Imperfecta (OI): Real-world Results from US Retrospective Claims (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1088;
- Bone Disease and Osteoporosis Associated with Pompe Disease (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1077;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among Postmenopausal Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies in the US (2019 (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1040;
- Exploring Risk Factors and Time-To-Onset Antiresorptive Drug-induced Osteonecrosis of the Jaw (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1039;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Is it possible to identify patients who will not respond to romosozumab? (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1036;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Efficacy and Safety of Romosozumab Treatment in Male and Female Patients with Osteoporosis. A Retrospective Cohort Study at a Single Clinical Center (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1029;
- Treatment-related changes in total hip bone mineral density and fracture risk reduction for trials with active control and sequential therapy: the FNIH-ASBMR-SABRE Project (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1028;
- Prior Treatment With Sequences of RANKL Inhibitor and Bisphosphonates Modifies the Tissue-Level Response of Vertebral Cancellous and Cortical Bone to Sclerostin Antibody in Ovariectomized Rats (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1026;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Effects of Anabolic Treatments with Teriparatide and Romosozumab on Bone in +/G610C Mouse Model of Adult Osteogenesis Imperfecta (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_879;
- ALP as a surrogate marker for estimating bone turnover in hemodialysis patients (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_748;
- Efficacy of Anti-Osteoporosis Therapy in Women Under and Over Age 75: an Analysis of the FNIH-ASBMR-SABRE Database (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_647;
- Factors associated with BMD response to 1-year treatment with anti-osteoporotic medications in osteoporosis management (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_646;
- Disability, functional limitation, and use of anti-fracture drug therapies in a cohort of 3651 U.S. adults with osteogenesis imperfecta (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_564;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Expected Fracture Outcomes and Associated Costs of Romosozumab Preceding or Following Alendronate in Postmenopausal Women at Very High Fracture Risk in the United States (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_552;
- Treatment-related changes in total hip bone mineral density and fracture risk reduction for trials with active control and sequential therapy: the FNIH-ASBMR-SABRE Project (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_551;
- Prior Treatment With Sequences of RANKL Inhibitor and Bisphosphonates Modifies the Tissue-Level Response of Vertebral Cancellous and Cortical Bone to Sclerostin Antibody in Ovariectomized Rats (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_547;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab and denosumab combination therapy in post-menopausal osteoporosis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_546;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Potent suppression of bone remodeling by denosumab does not blunt the anabolic response to romosozumab in mice (Meeting Room 714/716 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_405;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
A Comparative Study of the Effects of 12-Month Romosozumab Treatment versus Sequential Treatment with 6 Months of Romosozumab Followed by Denosumab in Korean population: A Multi-center Retrospective Study (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_355;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Rates of Concurrent BMD Responses at the Lumbar Spine and Total Hip in Patients Receiving Romosozumab or Teriparatide following Bisphosphonate Therapy: A Post Hoc Analysis of the Randomized Phase 3 STRUCTURE Trial (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_354;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Is Effective in Patients with Early-Onset Osteoporosis due to Variants in WNT1 or LRP5/6 (Meeting Room 801 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_279;
- | Strensiq (asfotase alfa) / AstraZeneca, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Monoclonal antibody anti-sclerostin for treatment of pelvic insufficiency fractures in adult hypophosphatasia: A case report. (Pubmed Central) - Aug 2, 2024
It not only helped increase bone density, but also help in the healing process of delayed-union and nonunion insufficiency fractures of the pelvis and prevented the occurrence of new fractures during the treatment period. To our knowledge, this is the first report describing the potential effect of Romosozumab on insufficiency fractures in patients with hypophosphatasia.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (clinicaltrials.gov) - Aug 1, 2024
P3, N=114, Not yet recruiting, Sponsor: Massachusetts General Hospital
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies. (Pubmed Central) - Jul 30, 2024
In this narrative review, we have summarized the studies investigating the change of sclerostin before and after kidney transplantation, the relationship between sclerostin and laboratory parameters, bone metabolism and vascular calcification in the context of kidney transplantation. We also pointed out the uncertainties, explained the causes of divergent findings and suggest further potential study topics regarding sclerostin in kidney transplantation.
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. (Pubmed Central) - Jul 28, 2024
It is imperative that new radiological and biological markers of fracture healing be identified. It is also important to synthesize clinical and basic science methodologies to assess fracture healing, so that a convergence of the two frameworks can be achieved.
- || Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical, Retrospective data, Review, Journal: Efficacy and Safety of Anti-Osteoporotic Agents Across CKD Stages: A Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) - Jul 26, 2024
However, this benefit is not apparent in stages 4 and 5, necessitating further research. Despite the absence of reported side effects in CKD patients, clinicians should carefully assess the suitability of these medications, considering individual risks and benefits.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Retrospective data, Journal: Romosozumab Followed by Denosumab Versus Denosumab Only: A Post Hoc Analysis of FRAME and FRAME Extension. (Pubmed Central) - Jul 23, 2024
Similar BMD and fracture outcomes were observed with PSW-MI and PSM sensitivity analyses. The sequence of Romo/DMAb resulted in greater BMD gains and higher probability of achieving T-scores > -2.5, significantly reduced new vertebral fracture incidence, and numerically lowered the incidence (not significant) of clinical, nonvertebral, and hip fractures versus DMAb only through 24
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
FDA event, Journal: AI-based 3D-QSAR model of FDA-approved repurposed drugs for inhibiting sclerostin. (Pubmed Central) - Jul 20, 2024
The Wnt pathway antagonist sclerostin and additional anti-sclerostin antibodies were discovered as a result of the development of the monoclonal antibody romosozumab...The test set demonstrated the model's robustness. This research may aid in the development of more effective sclerostin inhibitors that are synthesised using FDA-approved medications.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Myositis Ossificans of the Psoas Major Muscle After XLIF With Preoperative Administration of Romosozumab: A Case Report. (Pubmed Central) - Jul 19, 2024
We report a rare case of myositis ossificans in bilateral psoas major muscles following XLIF surgery, possibly influenced by intraoperative manipulation and romosozumab treatment. Etidronate administration may be effective, as with heterotopic ossification.
- || Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Retrospective data, Review, Journal: Utility of a bone health clinic in bridging the osteoporosis care gap: Prescribing habit review at an academic institution. (Pubmed Central) - Jul 18, 2024
Etidronate administration may be effective, as with heterotopic ossification. Establishing a bone health clinic dedicated to osteoporosis management leads to significantly higher prescription rates per provider, increased utilization of anabolic therapies compared to other specialties, and more male patients being treated-an often-neglected population in osteoporosis.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal, Biopsy: Evaluation of Romosozumab's Effects on Bone Marrow Adiposity in Postmenopausal Osteoporotic Women: Results from the FRAME Bone Biopsy Sub-Study. (Pubmed Central) - Jul 18, 2024
No relationship between the adipocyte parameters and the dynamic parameters of bone formation could be evidenced. In conclusion, based on the analysis of a small number of biopsies, no effect of romosozumab on bone marrow adiposity of iliac crest was identified after 2 and 12
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis. (Pubmed Central) - Jul 16, 2024
In conclusion, based on the analysis of a small number of biopsies, no effect of romosozumab on bone marrow adiposity of iliac crest was identified after 2 and 12 Treatment with romosozumab yields larger increases in bone mineral density than teriparatide after 12 months and a higher rate of completion.
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion, Trial completion date: Romosozumab in Women With Chronic SCI (clinicaltrials.gov) - Jul 14, 2024
P2, N=12, Completed, Sponsor: Northwestern University
Treatment with romosozumab yields larger increases in bone mineral density than teriparatide after 12 months and a higher rate of completion. Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Jun 2024
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Effect of RANKL on Lower Depressive Symptoms In Hemodialysis Patients. (Pubmed Central) - Jul 13, 2024
Higher plasma RANKL concentrations were significantly associated with lower depressive symptoms in HD patients.Trial registration WHO registry, No. KCT0003281, date: January 12, 2017.
- | Journal: Comparison table: Some drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
KCT0003281, date: January 12, 2017. No abstract available
- || Review, Journal: Drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available No abstract available
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Observational data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study. (Pubmed Central) - Jul 6, 2024
No abstract available The percent change in spine BMD at 12
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. (Pubmed Central) - Jun 26, 2024
The percent change in spine BMD at 12 Prior antiresorptive therapy blunted the BMD response to romosozumab, and the duration was correlated with BMD changes at both the lumbar spine and total hip.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P4 trial: Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study (clinicaltrials.gov) - Jun 23, 2024
P4, N=63, Not yet recruiting, Sponsor: Tuen Mun Hospital
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
COMPARATIVE EFFECTIVENESS OF OSTEOPOROSIS MEDICATIONS ON DISEASE ACTIVITY IN RHEUMATIC MUSCULOSKELETAL DISORDERS () - May 29, 2024 - Abstract #EULAR2024EULAR_3970;
Fracture risk might mediate the effect of osteoporosis medications and disease activity control. Larger pragmatic trials are warranted.
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
CLINICLAL EFFICACY OF SEQUENTIAL TREATMENT AFTER ROMOSOZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARISON WITH PRIMARY OSTEOPOROSIS FOR 24 MONTHS () - May 29, 2024 - Abstract #EULAR2024EULAR_3446;
Objectives: To evaluate the clinical efficacy of ROMO for 12 months and denosumab (DMB) for 12 months in patients with RA-OP comparison with primary osteoporosis (P-OP) for 24 months. Clinical efficacy of treatment with ROMO for 12months and DMB for 12months was extremely effective for RA-OP as well as for P-OP and has the high potential to be an important option in the treatment of RA-OP.
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification. (Pubmed Central) - May 24, 2024
However, in humans, while the antisclerostin antibody romosozumab inhibits bone resorption, biochemical parameters of endothelial activation and inflammation are not affected, and the incidence of aneurysms is not increased...Moreover, an increased number of vascular cells converted to osteogenic phenotypes results in increased plasma sclerostin concentrations. Therefore, plasma sclerostin derived from bone limits its importance as a global marker of vascular calcification.